Caffeine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Migraine W/ ergotamine: 100 mg. Mild CNS stimulant 50-100 mg, up to 200 mg. Not to be taken more often than 3 hrly. Max: 1 g/day
Dosage Details
Intravenous
Short-term treatment of neonatal apnoea of prematurity
Child: As citrate: 20 mg/kg (equivalent to 10 mg/kg caffeine) via IV infusion. Maintenance: 5 mg/kg daily. May also be given orally.

Oral
Migraine
Adult: 100 mg in combination with ergotamine.

Oral
Mild stimulant of the central nervous system
Adult: 50-100 mg up to 200 mg. Not to be taken more often than 3 hrly. Max: 1 g/day.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Peptic ulceration; symptomatic cardiac arrhythmias and/or palpitations; 1st several days to wk after an acute MI; neonates; pregnancy; lactation.
Adverse Reactions
Insomnia, restlessness, nervousness, mild delirium; nausea, vomiting, gastric irritation.
IM/IV/Parenteral/PO: C
Drug Interactions
Concurrent use may reduce the sedative/anxiolytic effect of benzodiazepines. Reduced levels when used with aminoglutethimide, carbamazepine, phenobarbital or rifampin. Increased levels when used with fluvoxamine, ketoconazole, rofecoxib, ciprofloxacin, norfloxacin or ofloxacin. β-adrenergic agonists, disulfiram, aspirin.
Lab Interference
False-positive elevations of serum urate; slight increases in urine levels of vanillylmandelic acid and catecholamines which give rise to false-positive diagnosis of pheochromocytoma or neuroblastoma; slight increases in urine levels of 5-hydroxyindoleacetic acid.
Action
Description: Caffeine, a methylxanthine, is a phosphodiesterase inhibitor. It has an antagonistic effect at central adenosine receptors. It is a CNS and resp stimulant. It has bronchodilating and diuretic properties and it facilitates the performance of muscular work.
Pharmacokinetics:
Absorption: Readily absorbed after oral admin.
Distribution: Widely distributed throughout the body.
Metabolism: Metabolised almost completely hepatically via oxidation, demethylation and acetylation.
Excretion: Excreted in the urine as 1-methyluric acid, 1-methylxanthine, 7-methylxanthine, 1,7-dimethylxanthine, 5-acetylamino-6-formylamino-3-methyluracil and other metabolites with only about 1% unchanged.
Disclaimer: This information is independently developed by MIMS based on Caffeine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in